3 completed, 1 recruiting, 1 withdrawn. 2 Phase 1, 1 Early Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Fallopian Tube Serous Neoplasm: new trials by email Literature Review of Fallopian Tube Serous Neoplasm trials Research Report on Fallopian Tube Serous Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial Chemotherapy, Laparotomy, Minimally Invasive Surgery - Advanced Ovarian Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Recruiting | M.D. Anderson Cancer Center | 580 | 2020-08-05 | 2026-09-14 |
| Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Laboratory Biomarker Analysis, Monitoring Device, Physical Activity - Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Neoplasm | Phase 2 | Completed | Roswell Park Cancer Institute | 9 | 2017-06-27 | 2021-09-02 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Hsp90 Inhibitor AT13387, Laboratory Biomarker Analysis, Pharmacological Study - Adult Solid Neoplasm, Estrogen Receptor Negative | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-03-01 | 2016-07-26 | |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Carcinoma, Fallopian Tube Carcinosarcoma | Phase 1 | Completed | National Cancer Institute (NCI) | 431 | 2009-10-28 | 2021-10-20 |
Fallopian Tube Neoplasms (5) · Ovarian Neoplasms (5) · Breast Neoplasms (1) · Brenner Tumor (1) · Triple Negative Breast Neoplasms (1)
Adnexal Diseases (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Fallopian Tube Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Gonadal Disorders (5) · Neoplasms (5) · Neoplasms by Site (5) · Ovarian Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5)
(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Carboplatin (1) · Cisplatin (1) · Disulfides (1) · Drug Therapy (1) · Exercise (1) · Immunoglobulin G (1) · Laparotomy (1) · Minimally Invasive Surgical Procedures (1) · Monitoring, Physiologic (1) · Paclitaxel (1) · Platinum (1) · Taxes (1)
National Cancer Institute (NCI) (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (4) · Canada (1) · Italy (1) · Mexico (1) · Netherlands (1)
Emese Zsiros (1) · Jose A Rauh-Hain (1) · Katherine M Bell-McGuinn (1) · Matthew S. Block, M.D., Ph.D. (1) · Panagiotis Konstantinopoulos (1)
PMID 31708167, PMID 33610319, PMID 39570589
P30CA006516 (1), P50CA136393 (1), U10CA027469 (1), U10CA180868 (1), UM1CA186709 (1)